Render Target: STATIC
Render Timestamp: 2024-10-24T10:27:21.958Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-07-30 16:37:09.444
Product last modified at: 2024-10-11T21:30:10.384Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

CDK12 Antibody #11973

Filter:
  • WB

    Supporting Data

    REACTIVITY H Mk
    SENSITIVITY Endogenous
    MW (kDa) 205
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CDK12 Antibody recognizes endogenous levels of total CDK12 protein. This antibody also cross-reacts with proteins of unknown origin at 48 and 53 kDa.

    Species Reactivity:

    Human, Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val492 of human CDK12 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Cyclin-dependent kinase 12 (CDK12/CRKRS/CRK7) is composed of a central CTD kinase domain, several proline-rich regions, and several amino-terminal arginine/serine (RS) motifs common to splicing factors (1). CDK12 is ubiquitously expressed and forms a complex with cyclin K that regulates phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (1-4). CDK12 is important for expression of a subset of long genes with high numbers of exons including some regulators of the DNA damage response, such as breast and ovarian cancer type 1 susceptibility protein 1 (BRCA1) and ataxia telangiectasia and Rad3-related (ATR) (3). Depletion of CDK12 results in spontaneous DNA damage and increased sensitivity to DNA damage agents (3). Research studies have shown that CDK12 is recurrently mutated in high-grade ovarian cancer (5,6). In addition, high levels of CDK12 are required to maintain pluripotency of embryonic stem cells (7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.